Myelodysplastic Syndrome (MDS) Center

Under the Direction of Dr. Peter Greenberg, Professor of Medicine (Hematology), the MDS Center provides special expertise for adults with Myelodysplastic Syndrome and its associated clinical problems.

This resource includes an outpatient clinic, experimental clinical trial structure and personnel within the Stanford Cancer Institute's Hematology Division which provides patients and their physicians access to:

  • Current information about the MDS Center
  • Current therapeutic approaches
  • Clinical trials for MDS
  • Knowledge of optimal usage of treatment therapies
  • Knowledge of treatment timing and patient selection


The major focus of the MDS Center is:

  • Coordination of patient management and scientific exchange with referring physicians
  • Patient/family education about MDS
  • Individualized prognosis-based treatment approaches
  • Quality of life issues in MDS


Management approaches at the MDS Center include use of recently developed national practice guidelines based on advances in prognostic evaluation of MDS patients through the National Comprehensive Cancer Network (NCCN). Differing types of treatment are available based on patients' specific subtype of MDS and related clinical problems.

Therapy, including supportive  (eg, transfusions and antibiotics as needed) and standard care as well as access to novel experimental agents are available through the Center. Treatment, including clinical trials, are provided through the MDS Center in the Hematology Clinic, the Infusion Treatment Area and Clinical Research Trial Unit. Currently active clinical trials for MDS may be viewed under MDS protocols on the Hematology Division Clinical Trials page. The clinical trials through the Stanford MDS Center are comprised of those for lower and high risk MDS patients: 


Therapy for lower risk patients:

  • Splice gene modulator (H3B-8800) treatment of splice gene mutated MDS and CMML patients
  • Luspatercept treatment of sideroblastic anemia MDS patients


Therapy for higher risk patients:

  • Aprea-246 treatment of TP53 mutated MDS and CMML patients
  • Splice gene modulator (H3B-8800) treatment of splice gene mutated MDS and CMML patients
  • Bone marrow transplantation



Peter Greenberg, MD, Professor of Medicine (Hematology), MDS Center Director

Steven Coutre, MD, Professor of Medicine (Hematology)

Jason Gotlib, MD, Professor of Medicine (Hematology)

David Iberri MD, Clinical Assistant Professor of Medicine (Hematology)

Lenn Fechter, RN, Clinic Nurse

Jack Taw, Clinical Research Associate

For appointments please call the Stanford Cancer Institute's Phone Number at 650.498.6000.